Limits...
A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus

Revised proposal for classification of antirheumatic therapies. With permission from Edmonds et al. (1993b), Arthritis and Rheumatism, John Wiley and Sons
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508364&req=5

Fig7: Revised proposal for classification of antirheumatic therapies. With permission from Edmonds et al. (1993b), Arthritis and Rheumatism, John Wiley and Sons

Mentions: A more elaborate proposal was published the following year (Edmonds et al. 1993b). Taking into account the emergent fact that management of RA “relates as much to an overall management strategy or drug combination as to a single agent”, the most significant modification from the previous year’s proposal was the substitution of the term “D-MARD”, with the term “DC-ART” or “disease-controlling antirheumatic therapy” (see Fig. 7). This was intended to encourage research on combination treatment programs in addition to single drugs (Edmonds et al. 1993b). Taking the place of DMARDs in the classificatory system, the concept would encompass “a drug or a strategy that prevents or significantly limits anatomic damage and maintains function and well-being at follow-up periods of 5, 10, 20 years, and even longer” (Edmonds et al. 1993b).Fig. 7


A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Revised proposal for classification of antirheumatic therapies. With permission from Edmonds et al. (1993b), Arthritis and Rheumatism, John Wiley and Sons
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508364&req=5

Fig7: Revised proposal for classification of antirheumatic therapies. With permission from Edmonds et al. (1993b), Arthritis and Rheumatism, John Wiley and Sons
Mentions: A more elaborate proposal was published the following year (Edmonds et al. 1993b). Taking into account the emergent fact that management of RA “relates as much to an overall management strategy or drug combination as to a single agent”, the most significant modification from the previous year’s proposal was the substitution of the term “D-MARD”, with the term “DC-ART” or “disease-controlling antirheumatic therapy” (see Fig. 7). This was intended to encourage research on combination treatment programs in addition to single drugs (Edmonds et al. 1993b). Taking the place of DMARDs in the classificatory system, the concept would encompass “a drug or a strategy that prevents or significantly limits anatomic damage and maintains function and well-being at follow-up periods of 5, 10, 20 years, and even longer” (Edmonds et al. 1993b).Fig. 7

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus